Financing
Proceeds From Repayments Of Lines Of Credit
Idexx Laboratories Proceeds From Repayments Of Lines Of Credit decreased by 49.1% to $132M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 89.9%, from $69.5M to $132M. Over 2 years (FY 2021 to FY 2024), Proceeds From Repayments Of Lines Of Credit shows a downward trend with a -100.0% CAGR.
Analysis
StatementCash Flow Statement
SectionFinancing
First reportedQ1 2019
Last reportedQ1 2026May 5, 2026
Metric ID:
financing_proceeds_from_repayments_of_lines_of_creditHistorical Data
17 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $18.38M | $18.38M | $18.38M | $326.5M | $211M | $22M | -$147.5M | -$167.5M | -$14M | $0 | $0 | $0 | $0 | $0 | $69.5M | $259.5M | $132M |
| QoQ Change | — | +0.0% | +0.0% | >999% | -35.4% | -89.6% | -770.5% | -13.6% | +91.6% | +100.0% | — | — | — | — | — | +273.4% | -49.1% |
| YoY Change | — | — | — | — | >999% | +19.7% | -145.2% | -179.4% | -163.6% | — | +100.0% | +100.0% | +100.0% | — | — | — | +89.9% |
Range-$167.5M – $326.5M
CAGR+63.7%
Avg YoY Growth+107.8%
Median YoY Growth+89.9%
Frequently Asked Questions
- What is Idexx Laboratories's proceeds from repayments of lines of credit?
- Idexx Laboratories (IDXX) reported proceeds from repayments of lines of credit of $132M in Q1 2026.
- How has Idexx Laboratories's proceeds from repayments of lines of credit changed year-over-year?
- Idexx Laboratories's proceeds from repayments of lines of credit increased by 89.9% year-over-year, from $69.5M to $132M.
- What is the long-term trend for Idexx Laboratories's proceeds from repayments of lines of credit?
- Over 2 years (2021 to 2024), Idexx Laboratories's proceeds from repayments of lines of credit has grown at a -100.0% compound annual growth rate (CAGR), from $73.5M to $0.